



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Michele CARGILL, et al.

Art Unit: 1645

Serial No.: 10/796,307

Examiner: TBA

Filed: March 10, 2004

Atty. Docket: CL001509

For: GENETIC POLYMORPHISMS ASSOCIATED  
WITH MYOCARDIAL INFARCTION, METHODS OF  
DETECTION AND USES THEREOF

**Statement Regarding Duty to Disclose Information Material To Patentability Under  
37 CFR 1.56 (a) and (b)**

Assistant Commissioner for Patents  
Washington, D.C. 20231


Sir:

Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

No fee is due for this submission. However, the Patent and Trademark Office is authorized to charge any necessary fees related to the processing of this application to Deposit Account No. 50-0970.


Respectfully submitted,

CELERA GENOMICS

  
Justin D. Karjala, Reg No. 43,704

Date: April 01, 2005

Celera Genomics  
45 West Gude Drive, C1-1#316  
Rockville, MD 20850  
Tel: 240-453-3812  
Fax: 240-453-3084



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

## Complete if Known

Application Number	10/796,307
Filing Date	March 10, 2004
First Named Inventor	CARGILL, Michele, et al.
Group Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	CL001509

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS


Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		DataBase DBSNP; NCBI; SNP 2 October 2001 (2001-10-02), XP002307296; Database-accession no. RS2681417	
		"SNP Report" The Consortium, "Online"; 15 August 2001 (2001-08-15), XP002307421	
		DataBase HGVBASE; EMBL; 9 November 2004 (2004-11-09), "SNP"; XP002307297; Database accession no. SNP001050724	
		DataBase EMBL "Online!"; 20 May 2001 (2001-05-20), "Sequence 1319 from patent US 6194150." XP002307395 retrieved from EBI accession no. EM_PAT: AR132894; Database accession no. AR132894	
		TAKAHASHI NAOYUKI et al.; "Evidence of cell-mediated cardiac myocyte injury involved in the heart failure of a patient with progressive systemic sclerosis"; Japanese Circulation Journal, vol. 63, no. 1, January 1999 (1999-01); pages 68-72, XP002307290; ISSN: 0047-1828	
		SEKO YOSHINORI, et al.; "Expression of costimulatory molecules B7-1, B7-2, and CD40 in the heart of patients with acute myocarditis and dilated cardiomyopathy"; Circulation, vol. 97, no. 7, 24 February 1998 (1998-02-24), pages 637-639, XP002307291; ISSN: 0009-7322	
		SALOMON B, et al.; "Complexities of CD28/B7: CTLA-4 Costimulatory Pathways in Autoimmunity and Transplantation"; Annual Reviews, Inc., US, vol. 19, 2001, pages 225-252; XP009004804; ISSN: 0732-0582; page 228 paragraph 2, page 235 paragraph 2, page 239 paragraph 2	
		WOOLLEY N., et al.; "CD80 (B7-1) and CD86 (B7-2) genes and genetic susceptibility to celiac disease"; European Journal of Immunogenetics, vol. 29, no. 4, August 2002 (2002-08), pages 331-333, XP002307292; ISSN: 0960-7420	
		MATSUSHITA M., et al.; "New Polymorphisms of Human CD80 and CD86: Lack of Association with Rheumatoid Arthritis and Systemic Lupus Erythematosus"; Genes and Immunity, October 2000, vol. 1, no. 7, October 2000 (2000-10), pages 428-434, XP008038592; ISSN: 1466-4879	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

**Complete if Known**

Application Number	10/796,307
Filing Date	March 10, 2004
First Named Inventor	CARGILL, Michele, et al.
Group Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	CL001509

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		DELNESTE YVES, et al.; "Detection of a Polymorphism in Exon 8 of the Human CD86 Gene" Immunogenetics, vol. 51, no. 8-9, July 2000 (2000-07), pages 762-763; XP002307294; ISSN: 0093-7711	
		WO 02/074989 A (GOUGH, Stephen; TODD John (GB); UEDA, Hironori (GB); Catalyst Biomedica; 26 September 2002 (2002-09-26)	
		CHENG SUZANNE, et al.; "A Multilocus Genotyping Assay for Candidate Markers of Cardiovascular Disease Risk" Genome Research, vol. 9, no. 10, October 1999 (1999-10), pages 936-949 XP002307295; ISSN: 1088-9051	
		WATTANAPITAYAKUL S K et al.; "Therapeutic Implications of Human Endothelial Nitric Oxide Synthase Gene Polymorphism"; Trends in Pharmacological Sciences, Elsevier Trends Journal, Cambridge, GB, vol. 22, no. 7, 1 July 2001 (2001-07-01), pages 361-368, XP004247879 ISSN: 0165-6147	
		SHIFFMAN DOV et al.; "Identification of Novel Genetic Markers Associated with Risk of Myocardial Infarction from a Genomic Scale Scan of Putative Functional Polymorphisms"; Journal of the American College of Cardiology; vol. 43, no. 5 Supplement A, 3 March 2004 (2004-03-03), page 488A, XP008039612	
		53 <sup>rd</sup> Annual Scientific Session of the American College of Cardiology; New Orleans, LA, USA; March 07-10, 2004; ISSN: 0735-1097	
		WO 2004/058052 A (APPLERA CORP; CARGILL, MICHELE (US); DEVLIN, JAMES J (US); IAKOUBOVA OL) 15 July 2004 (2004-07-15)	
		Copy of International Search Report and Written Opinion dated March 02, 2005	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.